Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian(Bloomberg (United States)), F. Stephen Hodi(Harvard University), Mario Sznol(Yale University), Evan J. Lipson(Bloomberg (United States)), Julie R. Brahmer(Johns Hopkins University), Philip D. Leming(Oncology Hematology Care), Janis M. Taube(Bloomberg (United States)), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Donald P. Lawrence(Massachusetts General Hospital), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Michael B. Atkins(Georgetown University), Drew M. Pardoll(Bloomberg (United States)), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Georgia Kollia(Bristol-Myers Squibb (United States)), Richard D. Carvajal(Northwell Health), William H. Sharfman(Johns Hopkins University), John D. Powderly(Carolina BioOncology Institute), Ashok Gupta, Harriet M. Kluger(Yale Cancer Center), David C. Smith(University of Michigan), David F. McDermott(Beth Israel Deaconess Medical Center)
Cited by 2,206
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k